Pyrazinoic Acid and Its n-Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating Tubercle Bacilli

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2006-11-13

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.01369-06PMID 17101678PMCID PMC1797748
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.

  2003cited by this paper
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

  2003cited by this paper
• The curious characteristics of pyrazinamide: a review.

  2003cited by this paper
• Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.

  2002cited by this paper
• Effects of Pyrazinamide on Fatty Acid Synthesis by Whole Mycobacterial Cells and Purified Fatty Acid Synthase I

  2002influential reference
• Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

  2000influential reference
• Role of Acid pH and Deficient Efflux of Pyrazinoic Acid in Unique Susceptibility of Mycobacterium tuberculosis to Pyrazinamide

  1999influential reference
• In Vitro Antimycobacterial Activity of 5-Chloropyrazinamide

  1998cited by this paper
• Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.

  1996cited by this paper
• Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus

  1996cited by this paper
• Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide

  1995cited by this paper
• Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.

  1995cited by this paper
• Lipophilic N-acylpyrazinamide derivatives: synthesis, physicochemical characterization, liposome incorporation, and in vitro activity against Mycobacterium avium-intracellulare.

  1991cited by this paper
• Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system.

  1990cited by this paper
• Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method

  1988cited by this paper
• The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.

  1978cited by this paper
• Pyrazinamide susceptibility and amidase activity of tubercle bacilli.

  1967cited by this paper
• Infrared spectroscopic studies of pigmented skin tumors.

  1954cited by this paper
• Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

  1954cited by this paper

• A scoping review about smoking, smoking cessation and their effects on anti-tuberculosis agents: insights into drug metabolisms, safety, and effectiveness

  2025cites this paper
• Drug-resistant strains of Mycobacterium tuberculosis: cell envelope profiles and interactions with the host

  2023cites this paper
• Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.

  2022cites this paper
• Drug resistant tuberculosis: Current scenario and impending challenges.

  2021cites this paper
• Towards Novel 3-Aminopyrazinamide-Based Prolyl-tRNA Synthetase Inhibitors: In Silico Modelling, Thermal Shift Assay and Structural Studies

  2021cites this paper
• The Bewildering Antitubercular Action of Pyrazinamide

  2020cites this paper
• Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis.

  2020cites this paper
• N-Pyrazinoyl Substituted Amino Acids as Potential Antimycobacterial Agents—the Synthesis and Biological Evaluation of Enantiomers

  2020cites this paper
• Derivatives of 3-Aminopyrazine-2-carboxamides: Synthesis, Antimicrobial Evaluation, and in Vitro Cytotoxicity

  2019cites this paper
• The application of metabolomics toward pulmonary tuberculosis research.

  2019cites this paper
• Design, synthesis and evaluation of biological activities of some novel anti-TB agents with bio-reducible functional group

  2019cites this paper
• Impact of the host environment on the antitubercular action of pyrazinamide

  2019cites this paper
• Novel insights into the pharmacometabonomics of first-line tuberculosis drugs relating to metabolism, mechanism of action and drug-resistance

  2018cites this paper
• Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis

  2018cites this paper
• Expression of a recombinant, 4'-Phosphopantetheinylated, active M. tuberculosis fatty acid synthase I in E. coli

  2018cites this paper
• Design, Synthesis and Evaluation of N-pyrazinylbenzamides as Potential Antimycobacterial Agents

  2018cites this paper
• Design, synthesis and antimycobacterial activity of hybrid molecules combining pyrazinamide with a 4-phenylthiazol-2-amine scaffold.

  2018cites this paper
• Fluoroquinolone derivatives and their anti-tubercular activities.

  2018cites this paper
• Targeting the Proteostasis Network for Mycobacterial Drug Discovery

  2018cites this paper
• Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains

  2018cites this paper
• Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care

  2018cites this paper
• The challenge of drug resistant tuberculosis

  2018cites this paper
• Quinoline Derivatives with Potential Activity Against Multidrug-resistant Tuberculosis

  2018cites this paper
• Deconvolution of Mycobacterium tuberculosis drug targets using high throughput screening approaches

  2018cites this paper
• Design and synthesis of 5-methylpyrazine-2-carbohydrazide derivatives: A new anti-tubercular scaffold

  2017cites this paper
• Detection of pyrazinamide resistance of Mycobacterium tuberculosis using nicotinamide as a surrogate.

  2017cites this paper
• 3-Substituted N-Benzylpyrazine-2-carboxamide Derivatives: Synthesis, Antimycobacterial and Antibacterial Evaluation

  2017cites this paper
• Mechanisms of Drug Action, Drug Resistance and Drug Tolerance in Mycobacterium tuberculosis: Expected Phenotypes from Evolutionary Pressures from a Highly Successful Pathogen

  2017cites this paper
• Update of Antitubercular Prodrugs from a Molecular Perspective: Mechanisms of Action, Bioactivation Pathways, and Associated Resistance

  2017cites this paper
• Antimycobacterial Agents: To Target or Not to Target

  2017cites this paper
• Targeting Phenotypically Tolerant Mycobacterium tuberculosis

  2017cites this paper
• The Forty-Sixth Euro Congress on Drug Synthesis and Analysis: Snapshot

  2017cites this paper
• 2 Chemotherapeutic Strategies and Targets Against Resistant TB

  2017cites this paper
• Mechanism and Treatment of Multi-Drug Resistance of Mycobacterium Tuberculosis: A Review

  2017cites this paper
• Synthesis, stereochemical, structural, and biological studies of a series of N′-(2r,4c-diaryl-3-azabicyclo[3.3.1]nonan-9-ylidene)pyrazine-2-carbohydrazides

  2017cites this paper
• Pharmacokinetics and Pharmacodynamics of the Tuberculosis Drugs

  2016cites this paper
• Missense Mutations in the Unfoldase ClpC1 of the Caseinolytic Protease Complex Are Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis

  2016cites this paper
• Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update.

  2016cites this paper
• A Note on Derivatives of Isoniazid, Rifampicin, and Pyrazinamide Showing Activity Against Resistant Mycobacterium tuberculosis

  2016cites this paper
• Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

  2016cites this paper
• Synthesis and biological activity of alkynoic acids derivatives against mycobacteria.

  2016cites this paper
• A High-Throughput Assay for Developing Inhibitors of PhoP, a Virulence Factor of Mycobacterium tuberculosis.

  2016cites this paper
• Identification of M. tuberculosis pncA gene single nucleotide polymorphisms conferring resistance to pyrazinamide.

  2016cites this paper
• Mycobacterial (Skin) Infections

  2016cites this paper
• Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates.

  2015cites this paper
• Differential Cocrystallization Behavior of Isomeric Pyridine Carboxamides toward Antitubercular Drug Pyrazinoic Acid

  2015cites this paper
• Synthesis and Antimicrobial Evaluation of 6‐Alkylamino‐N‐phenylpyrazine‐2‐carboxamides

  2015cites this paper
• A Case Report -INH Induced Erythroderma in A Patient with Tubercular Lymphadenitis

  2015cites this paper
• Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models

  2015cites this paper
• Novel lead generation of an anti-tuberculosis agent active against non-replicating mycobacteria: exploring hybridization of pyrazinamide with multiple fragments

  2015cites this paper
• New insights into TB physiology suggest untapped therapeutic opportunities

  2015cites this paper
• Adverse Drug Reactions to Anti-TB Drugs: Pharmacogenomics Perspective for Identification of Host Genetic Markers.

  2015cites this paper
• SYNTHESIS AND SCREENING OF POTENTIAL ANTIMICROBIAL COMPOUNDS

  2014cites this paper
• Drug Resistance Mechanisms in Mycobacterium tuberculosis

  2014cites this paper
• Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase.

  2014cites this paper
• N-Substituted 5-Amino-6-methylpyrazine-2,3-dicarbonitriles: Microwave-Assisted Synthesis and Biological Properties

  2014cites this paper
• Perspectives on tuberculosis pathogenesis and discovery of anti- tubercular drugs.

  2014cites this paper
• Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.

  2014cites this paper
• Pantothenate and Pantetheine Antagonize the Antitubercular Activity of Pyrazinamide

  2014cites this paper
• Artificial neural network modeling of antimycobacterial chemical space to introduce efficient descriptors employed for drug design

  2014cites this paper
• New Potentially Active Pyrazinamide Derivatives Synthesized Under Microwave Conditions

  2014cites this paper
• Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.

  2013cites this paper
• Base-Calling Algorithm with Vocabulary (BCV) Method for Analyzing Population Sequencing Chromatograms

  2013cites this paper
• Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution.

  2013cites this paper
• Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?

  2013cites this paper
• Synthesis, crystal structures, molecular simulations for hydrogen gas adsorption, fluorescent and antimicrobial properties of pyrazine-2,3-dicarboxylate complexes

  2013cites this paper
• Analogs of the Antituberculous Agent Pyrazinamide Are Competitive Inhibitors of NADPH Binding to M. tuberculosis Fatty Acid Synthase I

  2012cites this paper
• Synthesis, Characterization and Biological Activities of 2-Decylsulfonylacetamide Derivatives

  2012cites this paper
• Substituted N-Benzylpyrazine-2-carboxamides: Synthesis and Biological Evaluation †

  2012cites this paper
• Chemotherapeutic Interventions Against Tuberculosis

  2012cites this paper
• New Tuberculosis Drugs

  2012cites this paper
• Characterization of the Mycobacterium tuberculosis proteome by liquid chromatography mass spectrometry-based proteomics techniques: a comprehensive resource for tuberculosis research.

  2012cites this paper
• Chemotherapeutic Strategies and Targets Against Resistant TB

  2012cites this paper
• An unusual 3D metal–organic framework, {[Ag4(μ4-pzdc)2(μ-en)2]·H2O}n: C–H⋯Ag, N–H⋯Ag and (O–H)⋯Ag interactions and an unprecedented coordination mode for pyrazine-2,3-dicarboxylate

  2012cites this paper
• Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.

  2011cites this paper
• Contributions to the diagnosis of pirazinamide resistance in Mycobacterium tuberculosis

  2011cites this paper
• Mycobacterial fatty acid metabolism: identification of novel drug targets and chemotherapeutics.

  2011cites this paper
• Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.

  2011cites this paper
• Chapter 5: Recent Developments in the Study of Pyrazinamide: An Update

  2011cites this paper
• Mutually Exclusive Genotypes for Pyrazinamide and 5-Chloropyrazinamide Resistance Reveal a Potential Resistance-Proofing Strategy

  2010influential citation
• Evaluation of Colorimetric Methods Using Nicotinamide for Rapid Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis

  2010influential citation
• Syntheses, structural characterization and antimicrobial activities of novel cobalt-pyrazine-2,3-dicarboxylate complexes with N-donor ligands

  2010cites this paper
• Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes, and paraductions

  2010cites this paper
• Mycobacterium tuberculosis: drug resistance and future perspectives.

  2009cites this paper
• New frontiers in the therapy of tuberculosis: fighting with the global menace.

  2009cites this paper
• Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

  2009cites this paper
• Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes, and paraductions

  2009cites this paper
• 4-Hydroxy-2-quinolones. 168*. Synthesis, chemical and antitubercular properties of 1-R-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid pyrazin-2-ylamides

  2009cites this paper
• Synthesis and antimycobacterial evaluation of substituted pyrazinecarboxamides.

  2008cites this paper
• Inhibition of M. tuberculosis in vitro in monocytes and in mice by aminomethylene pyrazinamide analogs.

  2008cites this paper
• 7 Antibiotics and New Inhibitors of the Cell Wall

  2008cites this paper
• Clinical pharmacology of the antituberculosis drugs

  2008cites this paper
• Inhibition of Isolated Mycobacterium tuberculosis Fatty Acid Synthase I by Pyrazinamide Analogs

  2007cites this paper
• Antituberculosis drugs: ten years of research.

  2007cites this paper
• The Mycobacterium tuberculosis FAS‐II condensing enzymes: their role in mycolic acid biosynthesis, acid‐fastness, pathogenesis and in future drug development

  2007cites this paper
• Methods for Rapid Detection of Drug Resistant Mycobacterium tuberculosis

  2007cites this paper
• [Active drugs against Mycobacterium tuberculosis].

  2003cites this paper
• RESISTANCE IN MECHANISMS OF MYCO-BACTERIUM TUBERCULOSIS: INTRODUCING NEW CLASS OF THERAPEUTICS

  year unknowncites this paper
• A REVIEW ON PHARMACOTHERAPY FOR MULTIDRUG RESISTANCE TUBERCULOSIS

  year unknowncites this paper